List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/863052/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	National Survey of Drug-Resistant Tuberculosis in China. New England Journal of Medicine, 2012, 366, 2161-2170.	27.0	559
2	Saturated Very-Long-Chain Fatty Acids Promote Cotton Fiber and <i>Arabidopsis</i> Cell Elongation by Activating Ethylene Biosynthesis. Plant Cell, 2007, 19, 3692-3704.	6.6	258
3	Epidemiology of Extrapulmonary Tuberculosis among Inpatients, China, 2008–2017. Emerging Infectious Diseases, 2019, 25, 457-464.	4.3	167
4	Spoligotyping and Drug Resistance Analysis of Mycobacterium tuberculosis Strains from National Survey in China. PLoS ONE, 2012, 7, e32976.	2.5	117
5	A Mycobacterium tuberculosis surface protein recruits ubiquitin to trigger host xenophagy. Nature Communications, 2019, 10, 1973.	12.8	113
6	Study of the Rifampin Monoresistance Mechanism in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 893-900.	3.2	105
7	<i>In Vitro</i> Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	89
8	China's tuberculosis epidemic stems from historical expansion of four strains of Mycobacterium tuberculosis. Nature Ecology and Evolution, 2018, 2, 1982-1992.	7.8	83
9	Prevalence and Molecular Characterization of Fluoroquinolone-Resistant Mycobacterium tuberculosis Isolates in China. Antimicrobial Agents and Chemotherapy, 2014, 58, 364-369.	3.2	74
10	<i>In Vitro</i> Activity of Bedaquiline against Nontuberculous Mycobacteria in China. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	70
11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China. International Journal of Antimicrobial Agents, 2014, 43, 231-235.	2.5	66
12	Comparison of <i>In Vitro</i> Activity and MIC Distributions between the Novel Oxazolidinone Delpazolid and Linezolid against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis in China. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	59
13	Treatment of coronavirus disease 2019 in Shandong, China: a cost and affordability analysis. Infectious Diseases of Poverty, 2020, 9, 78.	3.7	49
14	Diagnostic Accuracy of the PURE-LAMP Test for Pulmonary Tuberculosis at the County-Level Laboratory in China. PLoS ONE, 2014, 9, e94544.	2.5	48
15	Evaluation of the Xpert MTB/RIF Assay in Gastric Lavage Aspirates for Diagnosis of Smear-negative Childhood Pulmonary Tuberculosis. Pediatric Infectious Disease Journal, 2014, 33, 1047-1051.	2.0	44
16	Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China. Scientific Reports, 2016, 6, 25330.	3.3	44
17	Multicenter Evaluation of Genechip for Detection of Multidrug-Resistant Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2013, 51, 1707-1713.	3.9	43
18	Epidemiology of pulmonary disease due to nontuberculous mycobacteria in Southern China, 2013–2016. BMC Pulmonary Medicine, 2018, 18, 168.	2.0	43

#	Article	IF	CITATIONS
19	Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China. International Journal of Antimicrobial Agents, 2015, 45, 491-495.	2.5	42
20	<i>M. tuberculosis</i> PknG manipulates host autophagy flux to promote pathogen intracellular survival. Autophagy, 2022, 18, 576-594.	9.1	40
21	<i>In Vitro</i> Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates. Antimicrobial Agents and Chemotherapy, 2016, 60, 393-399.	3.2	38
22	Relapse Versus Reinfection of Recurrent Tuberculosis Patients in a National Tuberculosis Specialized Hospital in Beijing, China. Frontiers in Microbiology, 2018, 9, 1858.	3.5	38
23	A novel method based on high resolution melting (HRM) analysis for MIRU–VNTR genotyping of Mycobacterium tuberculosis. Journal of Microbiological Methods, 2011, 86, 291-297.	1.6	37
24	GeneXpert MTB/RIF assay in the diagnosis of urinary tuberculosis from urine specimens. Scientific Reports, 2017, 7, 6181.	3.3	36
25	Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China. Journal of Infection, 2018, 76, 348-353.	3.3	36
26	Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1293-1296.	2.9	36
27	In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense. International Journal of Antimicrobial Agents, 2017, 49, 383-386.	2.5	35
28	Reduced Susceptibility of <i>Mycobacterium tuberculosis</i> to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China. Clinical Infectious Diseases, 2021, 73, e3391-e3397.	5.8	34
29	Genotyping and molecular characteristics of multidrug-resistant Mycobacterium tuberculosis isolates from China. Journal of Infection, 2015, 70, 335-345.	3.3	33
30	Nontuberculous mycobacterial pulmonary disease and associated risk factors in China: A prospective surveillance study. Journal of Infection, 2021, 83, 46-53.	3.3	33
31	Diversity of nontuberculous mycobacteria in eastern and southern China: aÂcross-sectional study. European Respiratory Journal, 2017, 49, 1601429.	6.7	32
32	Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. BMC Infectious Diseases, 2017, 17, 711.	2.9	31
33	Ethambutol Resistance as Determined by Broth Dilution Method Correlates Better than Sequencing Results with <i>embB</i> Mutations in Multidrug-Resistant Mycobacterium tuberculosis Isolates. Journal of Clinical Microbiology, 2014, 52, 638-641.	3.9	30
34	In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates. International Journal of Antimicrobial Agents, 2015, 45, 71-75.	2.5	29
35	GeneXpert MTB/RIF Outperforms Mycobacterial Culture in Detecting <i> Mycobacterium tuberculosis</i> from Salivary Sputum. BioMed Research International, 2018, 2018, 1-5.	1.9	29
36	Genotyping and Prevalence of Pyrazinamide- and Moxifloxacin-Resistant Tuberculosis in China, 2000 to 2010. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	28

#	Article	IF	CITATIONS
37	Comparison of Different Drug Susceptibility Test Methods To Detect Rifampin Heteroresistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2014, 58, 5632-5635.	3.2	26
38	Current status of new tuberculosis vaccine in children. Human Vaccines and Immunotherapeutics, 2016, 12, 960-970.	3.3	26
39	In vitro activity between linezolid and other antimicrobial agents against Mycobacterium abscessus complex. Diagnostic Microbiology and Infectious Disease, 2018, 90, 31-34.	1.8	26
40	Multicenter Evaluation of the Molecular Line Probe Assay for Multidrug Resistant Mycobacterium Tuberculosis Detection in China. Biomedical and Environmental Sciences, 2015, 28, 464-7.	0.2	25
41	<i>In Vitro</i> Activity of PBTZ169 against Multiple Mycobacterium Species. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	24
42	Diagnostic Yield of Oral Swab Testing by TB-LAMP for Diagnosis of Pulmonary Tuberculosis. Infection and Drug Resistance, 2021, Volume 14, 89-95.	2.7	24
43	Multicenter evaluation of the acid-fast bacillus smear, mycobacterial culture, Xpert MTB/RIF assay, and adenosine deaminase for the diagnosis of tuberculous peritonitis in China. International Journal of Infectious Diseases, 2020, 90, 119-124.	3.3	23
44	<i>Mycobacterium tuberculosis</i> protein kinase G acts as an unusual ubiquitinating enzyme to impair host immunity. EMBO Reports, 2021, 22, e52175.	4.5	23
45	Molecular characteristics of MDR Mycobacterium tuberculosis strains isolated inÂFujian, China. Tuberculosis, 2014, 94, 159-161.	1.9	22
46	Lung gene expression signatures suggest pathogenic links and molecular markers for pulmonary tuberculosis, adenocarcinoma and sarcoidosis. Communications Biology, 2020, 3, 604.	4.4	22
47	Mycobacterium kansasii Subtype I Is Associated With Clarithromycin Resistance in China. Frontiers in Microbiology, 2016, 7, 2097.	3.5	21
48	Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates. Frontiers in Microbiology, 2017, 8, 1768.	3.5	21
49	Clofazimine for Treatment of Extensively Drug-Resistant Pulmonary Tuberculosis in China. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	20
50	A 10-Year Comparative Analysis Shows that Increasing Prevalence of Rifampin-Resistant Mycobacterium tuberculosis in China Is Associated with the Transmission of Strains Harboring Compensatory Mutations. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	20
51	Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition. Antimicrobial Resistance and Infection Control, 2021, 10, 126.	4.1	20
52	Prevalence and treatment outcome of extensively drug-resistant tuberculosis plus additional drug resistance from the National Clinical Center for Tuberculosis in China: A five-year review. Journal of Infection, 2017, 75, 433-440.	3.3	19
53	Molecular Characterization of Prothionamide-Resistant Mycobacterium tuberculosis Isolates in Southern China. Frontiers in Microbiology, 2017, 8, 2358.	3.5	19
54	Treatment Outcome of a Shorter Regimen Containing Clofazimine for Multidrug-resistant Tuberculosis: A Randomized Control Trial in China. Clinical Infectious Diseases, 2020, 71, 1047-1054.	5.8	19

#	Article	IF	CITATIONS
55	Survey of Tuberculosis Hospitals in China: Current Status and Challenges. PLoS ONE, 2014, 9, e111945.	2.5	19
56	Risk factors for pulmonary cavitation in tuberculosis patients from China. Emerging Microbes and Infections, 2016, 5, 1-11.	6.5	18
57	Interpretation of Discordant Rifampicin Susceptibility Test Results Obtained Using GeneXpert vs Phenotypic Drug Susceptibility Testing. Open Forum Infectious Diseases, 2020, 7, ofaa279.	0.9	18
58	Metagenomic Next-Generation Sequencing Improves Diagnosis of Osteoarticular Infections From Abscess Specimens: A Multicenter Retrospective Study. Frontiers in Microbiology, 2020, 11, 2034.	3.5	17
59	Determination of inÂvitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates. Tuberculosis, 2015, 95, 839-842.	1.9	16
60	Molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis isolates circulating in Shaanxi, China. International Journal of Infectious Diseases, 2020, 99, 163-170.	3.3	16
61	Comparison of diagnostic accuracy of the GeneXpert Ultra and cell-free nucleic acid assay for tuberculous meningitis: A multicentre prospective study. International Journal of Infectious Diseases, 2020, 98, 441-446.	3.3	16
62	The Burden of MDR/XDR Tuberculosis in Coastal Plains Population of China. PLoS ONE, 2015, 10, e0117361.	2.5	16
63	Combining COLD-PCR and high-resolution melt analysis for rapid detection of low-level, rifampin-resistant mutations in Mycobacterium tuberculosis. Journal of Microbiological Methods, 2013, 93, 32-36.	1.6	15
64	ls rifampin resistance a reliable predictive marker of multidrug-resistant tuberculosis in China: A meta-analysis of findings. Journal of Infection, 2019, 79, 349-356.	3.3	15
65	<p>Comparison of in vitro Susceptibility of Mycobacteria Against PA-824 to Identify Key Residues of Ddn, the Deazoflavin-Dependent Nitroreductase from Mycobacterium tuberculosis</p> . Infection and Drug Resistance, 2020, Volume 13, 815-822.	2.7	15
66	Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis. International Journal of Infectious Diseases, 2021, 102, 392-396.	3.3	15
67	Evaluation of the MTBDRplus 2.0 assay for the detection of multidrug resistance among persons with presumptive pulmonary TB in China. Scientific Reports, 2017, 7, 3364.	3.3	14
68	Misdiagnosis of tuberculosis associated with some species of nontuberculous mycobacteria by GeneXpert MTB/RIF assay. Infection, 2017, 45, 677-681.	4.7	14
69	Comparison of Lowenstein-Jensen medium and MGIT culture system for recovery of Mycobacterium tuberculosis from abscess samples. Diagnostic Microbiology and Infectious Disease, 2020, 96, 114969.	1.8	14
70	Increased prevalence of levofloxacin-resistant Mycobacterium tuberculosis in China is associated with specific mutations within the gyrA gene. International Journal of Infectious Diseases, 2020, 92, 241-246.	3.3	14
71	Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination. Frontiers in Microbiology, 2021, 12, 655653.	3.5	14
72	An overview on tuberculosis-specific hospitals in China in 2009: results of a national survey. European Respiratory Journal, 2016, 47, 1584-1587.	6.7	13

#	Article	IF	CITATIONS
73	Clinical outcomes for multi- and extensively drug resistant tuberculosis patients with adjunctive resectional lung surgery in Beijing, China. Journal of Thoracic Disease, 2017, 9, 841-845.	1.4	13
74	<p>Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China</p> . Infection and Drug Resistance, 2019, Volume 12, 763-770.	2.7	12
75	Prevalence and risk factors of pulmonary nontuberculous mycobacterial infections in the Zhejiang Province of China. Epidemiology and Infection, 2019, 147, e269.	2.1	12
76	Generation of mycobacterial lipoarabinomannan-specific monoclonal antibodies and their ability to identify mycobacterium isolates. Journal of Microbiology, Immunology and Infection, 2021, 54, 437-446.	3.1	12
77	IMB-XMA0038, a new inhibitor targeting aspartate-semialdehyde dehydrogenase of <i>Mycobacterium tuberculosis</i> . Emerging Microbes and Infections, 2021, 10, 2291-2299.	6.5	12
78	Transregional movement of multidrug-resistant tuberculosis in north China: an underlying threat to tuberculosis control. Scientific Reports, 2016, 6, 29727.	3.3	11
79	<p>Para-aminosalicylic acid increases the susceptibility to isoniazid in clinical isolates of Mycobacterium tuberculosis</p> . Infection and Drug Resistance, 2019, Volume 12, 825-829.	2.7	11
80	Specific gyrA Gene Mutations Correlate with High Prevalence of Discordant Levofloxacin Resistance in Mycobacterium tuberculosis Isolates from Beijing, China. Journal of Molecular Diagnostics, 2020, 22, 1199-1204.	2.8	11
81	Comparing the Genotype and Drug Susceptibilities between Mycobacterium avium and Mycobacterium intracellulare in China. Biomedical and Environmental Sciences, 2017, 30, 517-525.	0.2	11
82	The effect of bacille Calmette-Guérin vaccination at birth on immune response in China. Vaccine, 2015, 33, 209-213.	3.8	10
83	First Insight into the Molecular Epidemiology ofMycobacterium tuberculosisIsolates from the Minority Enclaves of Southwestern China. BioMed Research International, 2017, 2017, 1-9.	1.9	10
84	Development and validation of external quality assessment panels for mycobacterial culture testing to diagnose tuberculosis in China. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1961-1968.	2.9	10
85	Epidemiology of skeletal tuberculosis in Beijing, China: a 10-year retrospective analysis of data. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 2019-2025.	2.9	10
86	Prevalence and Risk Factors of Subclinical Tuberculosis in a Low-Incidence Setting in China. Frontiers in Microbiology, 2021, 12, 731532.	3.5	10
87	Additional benefits of GeneXpert MTB/RIF assay for the detection of pulmonary tuberculosis patients with prior exposure to fluoroquinolones. Infection and Drug Resistance, 2019, Volume 12, 87-93.	2.7	9
88	The incremental value of bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in a high-burden urban setting. Journal of Infection, 2019, 79, 24-29.	3.3	9
89	Urinary proteomic analysis to identify a potential protein biomarker panel for the diagnosis of tuberculosis. IUBMB Life, 2021, 73, 1073-1083.	3.4	9
90	Outbreak of Mycobacterium tuberculosis Beijing Strain in a High School in Yunnan, China. American Journal of Tropical Medicine and Hygiene, 2020, 102, 728-730.	1.4	9

#	Article	IF	CITATIONS
91	HDAC6 contributes to human resistance against <i>Mycobacterium tuberculosis</i> infection via mediating innate immune responses. FASEB Journal, 2021, 35, e22009.	0.5	9
92	Comparison of Two Molecular Assays For Detecting Smear Negative Pulmonary Tuberculosis. Biomedical and Environmental Sciences, 2016, 29, 248-53.	0.2	9
93	Prevalence of tuberculosis among health care workers in tuberculosis specialized hospitals in China. Journal of Occupational Health, 2017, 59, 292-295.	2.1	8
94	Urinary metabolomic analysis to identify potential markers for the diagnosis of tuberculosis and latent tuberculosis. Archives of Biochemistry and Biophysics, 2021, 704, 108876.	3.0	8
95	Antimicrobial Susceptibility Testing and Molecular Characterization of Mycobacterium fortuitum Isolates in China. Biomedical and Environmental Sciences, 2017, 30, 376-379.	0.2	8
96	Resistance and tolerance of <scp><i>Mycobacterium tuberculosis</i></scp> to antimicrobial agents—How <scp><i>M</i>. <i>tuberculosis</i></scp> can escape antibiotics. WIREs Mechanisms of Disease, 2022, 14, .	3.3	8
97	Rapid molecular screening for multidrugâ€resistant tuberculosis in a resourceâ€limited region of China. Tropical Medicine and International Health, 2014, 19, 1259-1266.	2.3	7
98	A First Insight into the Genetic Diversity and Drug Susceptibility Pattern of <i> Mycobacterium tuberculosis </i> Complex in Zhejiang, China. BioMed Research International, 2016, 2016, 1-8.	1.9	7
99	Distinguishing Relapse From Reinfection With Whole-Genome Sequencing in Recurrent Pulmonary Tuberculosis: A Retrospective Cohort Study in Beijing, China. Frontiers in Microbiology, 2021, 12, 754352.	3.5	7
100	The feasibility of sputum transportation system in China: effect of sputum storage on the mycobacterial detection. Biomedical and Environmental Sciences, 2014, 27, 982-6.	0.2	7
101	Diagnostic dilemma of pulmonary tuberculosis among adults with severe mental illness in Beijing, China. BMC Infectious Diseases, 2017, 17, 83.	2.9	6
102	Feasibility of a new model for early detection of patients with multidrugâ€resistant tuberculosis in a developed setting of eastern China. Tropical Medicine and International Health, 2017, 22, 1328-1333.	2.3	6
103	High incidence of drugâ€resistant <i>Mycobacterium tuberculosis</i> in Hainan Island, China. Tropical Medicine and International Health, 2019, 24, 1098-1103.	2.3	6
104	An improved algorithm for rapid diagnosis of pleural tuberculosis from pleural effusion by combined testing with GeneXpert MTB/RIF and an anti-LAM antibody-based assay. BMC Infectious Diseases, 2019, 19, 548.	2.9	6
105	Performance of Xpert MTB/RIF in diagnosis of lymphatic tuberculosis from fresh and formaldehyde-fixed and paraffin embedded lymph nodes. Tuberculosis, 2020, 124, 101967.	1.9	6
106	Assessment of current diagnostic algorithm for detection of mixed infection with Mycobacterium tuberculosis and nontuberculous mycobacteria. Journal of Infection and Public Health, 2020, 13, 1967-1971.	4.1	6
107	Prevalence and Risk Factors Associated with Adverse Drug Reactions among Previously Treated Tuberculosis Patients in China. Biomedical and Environmental Sciences, 2017, 30, 139-142.	0.2	6
108	Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with Disputed <i>rpoB</i> Mutations and Discordant Susceptibility Phenotypes. Microbiology Spectrum, 2022, 10, e0208721.	3.0	6

#	Article	IF	CITATIONS
109	Dependence of Xpert MTB/RIF Accuracy for Detecting Rifampin Resistance in Bronchoalveolar Lavage Fluid on Bacterial Load: A Retrospective Study in Beijing, China. Infection and Drug Resistance, 2021, Volume 14, 2429-2435.	2.7	5
110	Combined IFN-Î ³ and IL-2 release assay for detect active pulmonary tuberculosis: a prospective multicentre diagnostic study in China. Journal of Translational Medicine, 2021, 19, 289.	4.4	5
111	Effect of Mixed Infections with Mycobacterium tuberculosis and Nontuberculous Mycobacteria on Diagnosis of Multidrug-Resistant Tuberculosis: A Retrospective Multicentre Study in China. Infection and Drug Resistance, 2022, Volume 15, 157-166.	2.7	5
112	A novel method for diagnosis of smear-negative tuberculosis patients by combining a random unbiased Phi29 amplification with a specific real-time PCR. Tuberculosis, 2015, 95, 411-414.	1.9	4
113	Antituberculosis drug prescribing for inpatients in a national tuberculosis hospital in China, 2011–2015. Journal of Global Antimicrobial Resistance, 2018, 14, 17-22.	2.2	4
114	Factors associated with negative T-SPOT.TB results among smear-negative tuberculosis patients in China. Scientific Reports, 2018, 8, 4236.	3.3	4
115	Change in prevalence and molecular characteristics of isoniazid-resistant tuberculosis over a 10-year period in China. BMC Infectious Diseases, 2019, 19, 689.	2.9	4
116	Successful management of Mycobacterium abscessus complex lung disease in an otherwise healthy infant. Infection and Drug Resistance, 2019, Volume 12, 1277-1283.	2.7	4
117	GeneXpert of stool versus gastric lavage fluid for the diagnosis of pulmonary tuberculosis in severely ill adults. Infection, 2019, 47, 611-616.	4.7	4
118	No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis. Diagnostic Microbiology and Infectious Disease, 2019, 94, 361-364.	1.8	4
119	<p>Epidemiology Of Human Pulmonary Infection With Nontuberculous Mycobacteria In Southeast China: A Prospective Surveillance Study</p> . Infection and Drug Resistance, 2019, Volume 12, 3515-3521.	2.7	4
120	<p>Rapid Diagnosis Of Multidrug-Resistant Tuberculosis Impacts Expenditures Prior To Appropriate Treatment: A Performance And Diagnostic Cost Analysis</p> . Infection and Drug Resistance, 2019, Volume 12, 3549-3555.	2.7	4
121	Rapid Detection of Ethambutol-Resistant Mycobacterium tuberculosis from Sputum by High-Resolution Melting Analysis in Beijing, China. Infection and Drug Resistance, 2020, Volume 13, 3707-3713.	2.7	4
122	Survival of patients with multidrug-resistant tuberculosis in Central China: a retrospective cohort study. Epidemiology and Infection, 2020, 148, e50.	2.1	4
123	<i>In Vitro</i> Susceptibility Testing of GSK656 against <i>Mycobacterium</i> Species. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	4
124	Genetic Diversity and Drug Susceptibility Profiles of Multidrug-Resistant Tuberculosis Strains in Southeast China. Infection and Drug Resistance, 2021, Volume 14, 3979-3989.	2.7	4
125	A novel automatic molecular test for detection of multidrug resistance tuberculosis in sputum specimen: A case control study. Tuberculosis, 2017, 105, 9-12.	1.9	3
126	An Overview of Tuberculosis-Designated Hospitals in China, 2009-2015: A Longitudinal Analysis of National Survey Data. BioMed Research International, 2019, 2019, 1-8.	1.9	3

#	Article	IF	CITATIONS
127	Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients. International Journal of Infectious Diseases, 2020, 100, 196-198.	3.3	3
128	Stepwise selection of mutation conferring fluroquinolone resistance: multisite MDR-TB cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1767-1771.	2.9	3
129	Highly Discriminative Genotyping of Mycobacterium abscessus Complex Using a Set of Variable Number Tandem Repeats in China. Frontiers in Microbiology, 2021, 12, 802133.	3.5	3
130	Rapid Detection of Clarithromycin and Amikacin Resistance in Mycobacterium abscessus Complex by High-Resolution Melting Curve Analysis. Microbiology Spectrum, 2022, 10, .	3.0	3
131	Impact of Xpert MTB/RIF on Outcomes of Adults Hospitalized With Spinal Tuberculosis: Findings From a Comparative Cohort in Beijing, China. Frontiers in Public Health, 0, 10, .	2.7	3
132	Cytokine-induced killer cell therapy as a promising adjunctive immunotherapy for multidrug-resistant pulmonary TB: a case report. Immunotherapy, 2018, 10, 827-830.	2.0	2
133	Comparison of in vitro synergistic effect between clarithromycin or azithromycin in combination with amikacin against Mycobacterium intracellulare. Journal of Global Antimicrobial Resistance, 2019, 18, 183-186.	2.2	2
134	Determining the optimal puncture site of CT-guided transthoracic needle aspiration biopsy for the diagnosis of tuberculosis. Journal of Thoracic Disease, 2020, 12, 3987-3994.	1.4	2
135	Effect of interval between food intake and drug administration at fasting condition on the plasma concentrations of first-line anti-tuberculosis drugs in Chinese population. Medicine (United States), 2020, 99, e22258.	1.0	2
136	External quality control of phenotypic drug susceptibility testing for Mycobacterium tuberculosis in China. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 871-875.	2.9	2
137	Factors associated with differential T cell responses to antigens ESAT-6 and CFP-10 in pulmonary tuberculosis patients. Medicine (United States), 2021, 100, e24615.	1.0	2
138	Comparative in vitro susceptibility of a novel fluoroquinolone antibiotic candidate WFQ-228, levofloxacin, and moxifloxacin against Mycobacterium tuberculosis. International Journal of Infectious Diseases, 2021, 106, 295-299.	3.3	2
139	Increased Expression of IL-10 in Peripheral Blood Mononuclear Cells Correlates with Negative Interferon-1 ³ Release Assay Results in Culture-Confirmed Tuberculosis Patients. Infection and Drug Resistance, 2021, Volume 14, 3135-3143.	2.7	2
140	Genotypes of Mycobacterium tuberculosis isolates circulating in Shaanxi Province, China. PLoS ONE, 2020, 15, e0242971.	2.5	2
141	Elevated Natural Killer Cell-Mediated Cytotoxicity Is Associated with Cavity Formation in Pulmonary Tuberculosis Patients. Journal of Immunology Research, 2021, 2021, 1-8.	2.2	2
142	Inducible Resistance to Amikacin in Mycobacterium abscessus Isolated in Beijing, China. Infection and Drug Resistance, 2022, Volume 15, 2287-2291.	2.7	2
143	Minimum inhibitory concentration of cycloserine against Mycobacterium tuberculosis using the MGIT 960 system and a proposed critical concentration. International Journal of Infectious Diseases, 2022, 121, 148-151.	3.3	2
144	Multicenter feasibility study to assess external quality panels for molecular diagnostics for tuberculosis in China. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 339-343.	2.9	1

#	Article	IF	CITATIONS
145	Occurrence of multidrug-resistant tuberculous meningitis associated with injury during spinal surgery: A case report. Journal of Infection and Public Health, 2020, 13, 1586-1588.	4.1	1
146	Household Clusters of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Suzhou, China. BioMed Research International, 2021, 2021, 1-7.	1.9	1
147	Rv3737 is required for Mycobacterium tuberculosis growth in vitro and in vivo and correlates with bacterial load and disease severity in human tuberculosis. BMC Infectious Diseases, 2022, 22, 256.	2.9	1
148	Molecular Characteristic of Both Levofloxacin and Moxifloxacin Resistance in <i>Mycobacterium tuberculosis</i> from Individuals Diagnosed with Preextensive Drug-Resistant Tuberculosis. Microbial Drug Resistance, 2021, , .	2.0	1
149	Nosocomial Infection Surveillance in a Tuberculosis Specialized Hospital in China. Biomedical and Environmental Sciences, 2017, 30, 691-694.	0.2	1
150	High Incidence of Psychiatric Disorders Associated with Cycloserine Treatment of Multidrug-Resistant Tuberculosis Patients: A Cohort Study in Beijing, China. Infection and Drug Resistance, 0, Volume 15, 3725-3732.	2.7	1
151	Upregulation of PD-1 expression on circulating CD8+ but not CD4+ T cells is associated with tuberculosis infection in health care workers. BMC Immunology, 2021, 22, 39.	2.2	0
152	Bipolar Distribution of Minimum Inhibitory Concentration of Q203 Across Mycobacterial Species. Microbial Drug Resistance, 2021, 27, 1013-1017.	2.0	0